LLLei Liu

Lei Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lei Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Jinli Zhang

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China

    2 shared publications
  • Baoru Hu

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China

    1 shared publication
  • Chun Feng Li

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province, 150081, China

    1 shared publication
  • Chunbo Zhao

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province, 150081, China

    1 shared publication
  • Di Wu

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China

    1 shared publication
  • Fanwei Kong

    Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China

    1 shared publication

Latest Publications

  • Open Access

    Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors

    by Jinli Zhang, Lu Yang, Fanwei Kong, Di Wu, Baoru Hu, Jie Yang, Jiaxin He, Lei Liu

    Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or metastatic MSI-H colorectal cancer, but some people still show drug resistance or progression. Combined immunotherapy has been shown to expand the benefit population in non-small-cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), and other tumors while reducing the incidence of hyper-progression disease (HPD). Nevertheless, advanced CRC with MSI-H remains rare. In this article, we describe a case of an elder patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity. Our case provides a new treatment option for MSI-H CRC with multiple risk factors of HPD and highlights the importance of predictive biomarkers in personalized immunotherapy.


  • Open Access

    Green walnut husk extracts Proliferation and Migration in Gastric Cancer

    by Jiarong Zhang, Jinli Zhang, Chunbo Zhao, Hong Sui, Chun Feng Li, Lili Zhong, Qingxin Zhou, Yuxian Bai, Shijia An, Xiaoxue Du, et al.

    Background: In the past few decades, natural products have become an increasingly important source of potential anti-cancer agents. The green walnut husk(GWH) extracts have been reported to inhibit multiple tumor cells and might be a promising chemopreventive agent in human neoplasia. However, it is not clear whether GWH extracts inhibit gastric cancer.